Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 IV dose-finding vs tolvaptan 15 mg in congestive heart failure
jRCT2080223620Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolvaptan sodium phosphate in heart failure (HF) (5 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: OPC-41061 Cmax on Day 1 and OPC-41061 AUC24h on Day 1. Started Aug 2017; status: completed.
02
Drugs
tolvaptan sodium phosphate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT2080223620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223620.